Last reviewed · How we verify
Dehydrated Alcohol Injection, USP — Competitive Intelligence Brief
phase 3
Sclerosing agent / Ablative agent
Oncology / Interventional Radiology
Small molecule
Live · refreshed every 30 min
Target snapshot
Dehydrated Alcohol Injection, USP (Dehydrated Alcohol Injection, USP) — Ablative Solutions, Inc.. Dehydrated alcohol causes tissue ablation and coagulation necrosis through protein denaturation and cellular dehydration when injected directly into target tissue.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dehydrated Alcohol Injection, USP TARGET | Dehydrated Alcohol Injection, USP | Ablative Solutions, Inc. | phase 3 | Sclerosing agent / Ablative agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Sclerosing agent / Ablative agent class)
- Ablative Solutions, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dehydrated Alcohol Injection, USP CI watch — RSS
- Dehydrated Alcohol Injection, USP CI watch — Atom
- Dehydrated Alcohol Injection, USP CI watch — JSON
- Dehydrated Alcohol Injection, USP alone — RSS
- Whole Sclerosing agent / Ablative agent class — RSS
Cite this brief
Drug Landscape (2026). Dehydrated Alcohol Injection, USP — Competitive Intelligence Brief. https://druglandscape.com/ci/dehydrated-alcohol-injection-usp. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing